API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Under the terms of the agreement, Basilea sells and transfers all rights to BAL101553 (lisavanbulin) to the Glioblastoma Foundation. It is currently being evaluated for the treatment of neoplasms.
Lead Product(s): Lisavanbulin
Therapeutic Area: Oncology Product Name: BAL101553
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Glioblastoma Foundation Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 20, 2024
Details:
In preclinical studies, lisavanbulin demonstrated in-vitro and in-vivo activity against diverse treatment-resistant cancer models, including tumors refractory to conventional approved therapeutics and radiotherapy.
Lead Product(s): Lisavanbulin
Therapeutic Area: Oncology Product Name: BAL101553
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2021